AIDS:研究发现HIV患者CD4细胞计数与缺血性卒中风险有关

2014-06-26 佚名 睿医资讯

一项为期15年的研究结果显示,HIV阳性的个体缺血性卒中的风险增高40%,但若此类个体CD4细胞计数增高,则相应风险与HIV阴性个体相似。相关研究最近发表于国际AIDS学会官方杂志AIDS上。这项研究由1996年开始至2011年结束,涉及仅2.5万HIV阳性个体。缺血性卒中的发生是由于血管内斑块形成所致,可导致血管狭窄或堵塞,阻断脑部的血液和氧气供应。CD4细胞计数低于500提示对抗感染和炎症反应

一项为期15年的研究结果显示,HIV阳性的个体缺血性卒中的风险增高40%,但若此类个体CD4细胞计数增高,则相应风险与HIV阴性个体相似。

相关研究最近发表于国际AIDS学会官方杂志AIDS上。这项研究由1996年开始至2011年结束,涉及仅2.5万HIV阳性个体。

缺血性卒中的发生是由于血管内斑块形成所致,可导致血管狭窄或堵塞,阻断脑部的血液和氧气供应。CD4细胞计数低于500提示对抗感染和炎症反应的白细胞数量较少,是免疫系统功能低下的标志。

这项研究发现,近期CD4细胞计数是最强的HIV特异性危险因子,这表示免疫缺陷可影响缺血性卒中的发生风险。而且值得注意的是,近期CD4细胞计数≥500的HIV阳性个体,缺血性卒中的发生风险并未高于HIV阴性个体。

如果免疫缺陷和缺血性卒中风险间存在因果关系,那么早期、持续进行抗逆转录病毒治疗以维持免疫功能,并联合其他卒中危险因素的缓解,或可使HIV阳性个体的缺血性卒中风险降至与一般人群相似的水平。

近期有观点认为应减少或终止对进行病毒抑制治疗的HIV阳性个体进行CD4水平监测。本项研究提示,维持免疫功能或许能预防缺血性卒中的发生,CD4细胞计数或许不仅仅可用于HIV病情的监测。

原始出处:



Marcus JL1, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, Klein DB, Quesenberry CP Jr, Towner WJ, Silverberg MJ.HIV infection and incidence of ischemic stroke.AIDS. 2014 Jun 17. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2015-03-04 qidongfanjian
  4. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-09-28 wjywjy
  7. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1753075, encodeId=caac1e530752f, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sun Sep 28 21:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892617, encodeId=a74a189261e28, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri May 22 10:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864205, encodeId=6abf1864205db, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Mar 04 23:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805991, encodeId=ccca1805991f7, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Jan 05 20:16:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068340, encodeId=d9c12068340fa, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Mar 04 16:16:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033805, encodeId=0d9f203380532, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Sep 28 01:16:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003338, encodeId=77182003338bb, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Aug 09 01:16:00 CST 2014, time=2014-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281175, encodeId=f38b12811e5d8, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365599, encodeId=cfa81365599a6, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 00:16:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 cooco

相关资讯

BMJ:营养补充改善艾滋者健康状况

在非洲大约生活着2500万HIV感染者,其中大部分人都已经开始进行抗逆转录病毒疗法(ART)治疗疾病了;ART 可以明显减少个体AIDS 相关的死亡数。近日,刊登在国际杂志BMJ上的一篇研究论文中,来自哥本哈根大学的研究人员通过研究表示,在患者进行ART疗法的前三个月时每日的营养补充对于改善HIV患者的健康状况非常关键。 研究者Mette Frahm 

Nature:HIV研究遭遇非洲之困

4月12日,一个周六的早晨,10名警察突击搜查了Maaygo—— 一家位于肯尼亚西部基苏木市住宅区的研究男性健康和HIV(艾滋病病毒)/AIDS(艾滋病)的组织。员工眼睁睁地看着警察没收了传单甚至在避孕套使用方法示范中使用的阴茎模型。警察逮捕了该组织的负责人和财务主管以及一名成员,理由是“非法从事有关性取向方面的职业”。 当地同性恋权利保护组织负责人Daniel Onyango赶到警局解释,传

PLoS Med:超龄儿童艾滋病检测遇到的麻烦

近日,刊登在国际杂志PLoS Medicine上的一项研究中,来自伦敦城市学校卫生与热带医学院的研究人员通过研究表示,对少儿隐私和监护的关心会阻碍诊所对儿童HIV的检测。该研究结果对于如何提高对弱势群体的照顾提供了一些非常重要的信息。全球有超过三百万的儿童感染了艾滋病(90%在撒哈拉以南的非洲地区),2011年每天约有1000名儿童感染艾滋病。大龄儿童通常不知道艾滋病毒是在婴儿出生时通过母婴途径传

Nature:HIV试验遭受抨击

批评家们针对允许孕妇接受低于其所在国家标准的治疗方法的伦理学问题提出了质疑。 由于HIV病毒感染者的治疗方法突飞猛进,一些医生和激进主义分子强烈要求美国国立过敏症和传染病研究所(National Institute of Allergy and Infectious Diseases, NIAID)停止一项对比性试验,不要再比较新老疗法阻断HIV病毒母婴传播的效果了。 促进各地母婴生存(Pro

EASL 2014:MK-5172和MK-8742可有效治疗HCV1型和HIV共感染者

MK-5172是HCV NS3/4蛋白酶抑制剂。MK-8742是HCV NS5A抑制剂。来自巴塞罗那的研究人员发现,MK-5172和MK-8742+/-利巴韦林(RBV)可用于治疗HCV1型和HIV共感染患者。据悉,这是第一份HCV和HIV共感染患者服用口服药物治疗的报道。 该研究人群为丙肝初治、非肝硬化合并HIV感染的患者。患者正在进行稳定的抗逆转录病毒疗法(罗特格韦+替诺福韦或阿巴卡韦)。患

Science:研究者或可构建一种更好的HIV疫苗

刊登在近日的国际杂志Science上的一篇研究报告中,来自国外的研究人员设计了一种免疫原,它代表了朝着制造一种可在人体内释放对抗HIV-1的广谱中和抗体疫苗所迈出的重要的第一步。 Joseph Jardine及其同事对近些年来在世界各地的病人体内分离出的这种高度有效的广谱中和抗体——它对HIV-1的gp120包膜蛋白具有特异性——进行了研究。 研究人员接着想出了一种方法来设计可与这些高度变异的